Text Size

Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00803660
First received: December 3, 2008
Last updated: July 8, 2009
Last verified: July 2009
History of Changes

December 3, 2008
July 8, 2009
November 2008
Not Provided
  • The number of patients achieving the BP<130/80 mmHg [ Designated as safety issue: No ]
  • The percentage of patients achieving the BP<130/80 mmHg [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00803660 on ClinicalTrials.gov Archive Site
  • The number and percentage of patients achieving the BP<130/80 mmHg by treatment groups [ Designated as safety issue: No ]
  • The number and percentage of patients achieving HbA1c=<7% [ Designated as safety issue: No ]
  • The number and percentage of patients achieving the FPG<110 mg% [ Designated as safety issue: No ]
  • The association between unachievement of BP<130/80 mmHg and other factors (age, gender, CV risk factors, CV and diabetes history, duration of type of treatment...) [ Designated as safety issue: No ]
  • The number and percentage of patients with positive proteinuria by treatment groups [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.

Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=<7%. To observe the proportion of patients achieving fasting plasma glucose<110 mg%. To identify factors for not achieving BP<130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .
Not Provided
Observational
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

type 2 diabetic patients who are currently using antihypertensive treatment for at least 3 months, with same regimen for a minimum of 4 weeks prior to the survey
  • Hypertension
  • Type 2 Diabetes
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1060
May 2009
Not Provided

Inclusion Criteria:

  • Provision of written informed consent
  • Patient was diagnosed with type 2 diabetes
  • Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey

Exclusion Criteria:

  • Patients are critically ill, had mental health problems or difficulty in communication
  • Patients who are unwilling or unable to provide informed consent
  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Vietnam
 
NCT00803660
NIS-CVN-DUM-2008/1
No
Vo Viet Tuan, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Principal Investigator: Dang Van Phuoc, PhD. University of Medicine and Pharmacy of HCMC
Principal Investigator: Pham Nguyen Vinh, PhD. Tam Duc Heart Hospital
Principal Investigator: Pham Gia Khai, PhD. Vietnam Heart Association
Principal Investigator: Nguyen Thy Khue, PhD Endocrinology and Diabetes Association of HCMC
AstraZeneca
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP